Biologic activity of tamoxifen at low doses in healthy women

Journal of the National Cancer Institute

Volumn 90, Issue 19, 1998, Pages 1461-1467

  Decensi, Andrea ^a   Bonanni, Bernardo ^a   Guerrieri Gonzaga, Aliana ^a   Gandini, Sara ^a   Robertson, Chris ^a   Johansson, Harriet ^b   Travaglini, Roberto ^c   Sandri, Maria Teresa ^a   Tessadrelli, Antonella ^d   Farante, Gabriel ^a   Salinaro, Federica ^d   Bettega, Donato ^e   Barreca, Antonina ^b   Boyle, Peter ^a   Costa, Alberto ^a   Veronesi, Umberto ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Italian League Against Cancer   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; CHOLESTEROL; FIBRINOGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; SOMATOMEDIN C; TAMOXIFEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER PREVENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0032494478     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.19.1461     Document Type: Article

References (60)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451-67.
2. Jordan VC. Tamoxifen: the herald of a new era of preventive therapeutics. J Natl Cancer Inst 1997;89:747-9.
3. Smigel K. Breast cancer prevention trial shows major benefit, some risk. J Natl Cancer Inst 1998;90:647-8.
4. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
5. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995;87:645-51.
6. van Leeuwen FE, Benraadt J. Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343: 448-52.
7. Lonning PE, Lien EA. Pharmacokinetics of anti-endocrine agents. Cancer Sury 1993;17: 343-70.
8. Coezy E, Borgna JL, Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 1982;42: 317-23.
9. Sutherland RL, Watts CK, Hall RE, Ruenitz PC. Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells. J Steroid Biochem 1987;27:891-7.
10. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994;86:1534-9.
11. Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U.. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med 1996;156: 1806-10.
12. Love RR, Surawicz TS, Williams EC. Antithrombin III level, fibrinogen level and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med 1992;152:317-20.
13. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
14. Coletti RB, Roberts JD, Devlin JT, Copeland KC. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 1989;49:1882-4.
15. Pollak M, Costantino J, Polychronakos C, Blauer SA, Guyda H, Redmond C, et al. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 1990;82:1693-7.
16. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93-7.
17. Stokes YM, Salmond CE, Carpenter LM, Weby TJ. Stability of total cholesterol, high-density-lipoprotein cholesterol, and triglycerides in frozen sera. Clin Chem 1986;32:995-9.
18. WHO Expert Committee on specifications for pharmaceutical preparations. World Health Organ Tech Rep Ser 1996;863:1-194.
19. Bostom AG, Gagnon DR, Cupples LA, Wilson PW, Jenner JL, Ordovas JM, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation 1994;90:1688-95.
20. Levine DM, Sloan BJ, Donner JE, Lorenz JD, Heinzerling RH. Automated measurement of lipoprotein(a) by immunoturbidimetric analysis. Int J Clin Lab Res 1992;22:173-8.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
22. Garnero P, Grimaux M, Seguin P, Dehnas PD. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 1994;9:255-64.
23. Daughaday WH, Mariz IK, Blethen SL. Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. J Clin Endocrinol Metab 1980;51:781-8.
24. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990;82:1916-24.
25. Love RR, Mamby CC, Feyzi JM. Tamoxifen-induced decrease in total cholesterol with 2 weeks of treatment. J Natl Cancer Inst 1993; 85:1344-5.
26. Ruan W, Newman CB, Kleinberg DL. Intact and amino-terminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development. Proc Natl Acad Sci U S A 1992;89:10872-6.
27. van der Burg B, Isbrucker L, van Selm-Miltenburg AJ, de Laat SW, van Zoelen EJ. Role of estrogen-induced insulin-like growth factors in the proliferation of human breast cancer cells. Cancer Res 1990;50:7770-4.
28. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC Jr, Allred DC, et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989;84:1418-23.
29. Peyrat J,. Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 1993; 29A:492-7.
30. Bruning PF, Van Doom J, Bonfrer JM, Van Noord PA, Korse CM, Linders TC, et al. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 1995;62:266-70.
31. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentration of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
32. Yandell BS. Practical data analysis for designed experiments. London: Chapman & Hall; 1997.
33. SAS for Windows version 6.11. Cary (NC): SAS Institute; 1995.
34. Kelloff GJ, Johnson JR, Crowell JA, Boone CW, DeGeorge JJ, Steele VE, et al. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 1995;4:1-10.
35. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997;278: 1073-7.
36. Li D, Dragan Y, Jordan VC, Wang M, Pitot HC. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res 1997; 57:1438-41.
37. Hemminki K, Rajaniemi H, Lindhal B, Moberger B. Tamoxifcn-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 1996;56:4374-7.
38. Decensi A, Fontana V, Bruno S, Gustavino S, Gatteschi B, Costa A. Effect of tamoxifen on endometrial proliferation. J Clin Oncol 1996; 14:434-40.
39. Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994;7:7S-12S.
40. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991;84: 613-7.
41. Gillum RF, Ingram DD, Makuc DM. White blood cell count, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J 1993;125:855-63.
42. Torrisi R, Parodi S, Fontana V, Pensa F, Casella C, Barreca A, et al. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients. Int J Cancer 1998;76:787-90.
43. Kauffman RF, Bensch WR, Roudebush RE, Cole HW, Bean JS, Phillips DL, et al. Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator. J Pharmacol Exp Ther 1997;280:146-53.
44. Turner RT, Riggs BL, Spelsberg TC. Skeletal effects of estrogen. Endocr Rev 1994;15: 275-300.
45. Blobel GA, Sieff CA, Orkin SH, Ligand-dependent repression of the erythroid transcription factor GATA-1 by the estrogen receptor. Mol Cell Biol 1995;15:3147-53.
46. Tarantino MD, Kunicki TJ, Nugent DJ. The estrogen receptor is present in human megakaryocytes. Ann N Y Acad Sci 1994;714: 293-6.
47. Ben-Hur H, Mor G, Insler V, Blickstein I, Amir-Zaltsman Y, Sharp A, et al. Menopause is associated with a significant increase in blood monocyte number and a relative decrease in the expression of estrogen receptors in human peripheral monocytes. Am J Reprod Immunol 1995;34:363-9.
48. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, et al. Estrogen regulation of the insulin-like growth factor 1 gene transcription involves an AP-1 enhancer. J Biol Chem 1994;269:16433-42.
49. Powles TJ, Jones AL, Ashley SE, O'Brien ME, Tidy VA, Treleavan J, et al. The Royal Marsden Hospital pilot tamoxiten chemoprevention trial. Breast Cancer Res Treat 1994;31: 73-82.
50. Nayfield SG. Tamoxifen's role in chemoprevention of breast cancer: an update. J Cell Biochem Suppl 1995;22:42-50.
51. Pollak M, Powles TJ, Baum M, Sacks N. Tamoxifen used as a chemopreventative agent lowers serum IGF-I levels [abstract]. Proc Am Assoc Cancer Res 1993;34:255.
52. Friedl A, Jordan VC, Pollak M. Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 1993;29A:1368-72.
53. Maltoni C, Minardi F, Belpoggi F, Pinto C, Lenzi A, Filippini F. Experimental results on the chemopreventive and side effects of tamoxifen using a human-equivalent animal model. In: Maltoni C, Soffritti M, Davis W, editors. The scientific bases of cancer chemoprevention. Amsterdam: Elsevier Sciences; 1996. p. 197-217.
54. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996;10: 905-12.
55. Ke HZ, Chen HK, Simmons HA, Qi H, Crawford DT, Pirie CM, et al. Comparative effects of droloxifene, tamoxifen and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone 1997; 20:31-9.
56. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 1991;83:1488-91.
57. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive -mors. N Engl J Med 1989;320:479-84.
58. Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991;151:1842-7.
59. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7 [see comments in: Fileihan GE. Tissue-specific estrogens - the promise for the future. N Engl J Med 1997;337: 1686-7].
60. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7 [see comments in: Fileihan GE. Tissue-specific estrogens - the promise for the future. N Engl J Med 1997;337: 1686-7].